NewsBenzingaImmunityBioとRafa Laboratories、イスラエル保健省がANKTIVAを承認と発表 ANKTIVAはBCGに不応性のCISを有する乳頭腫瘍の有無を問わない成人の非筋層浸潤性膀胱がん（NMIBC）治療においてBCGとの併用で適応 ImmunityBioとRafa Laboratories、イスラエル保健省がANKTIVAを承認と発表 ANKTIVAはBCGに不応性のCISを有する乳頭腫瘍の有無を問わない成人の非筋層浸潤性膀胱がん（NMIBC）治療においてBCGとの併用で適応 Benzinga 2026.11.09 12:23 (GMT+0) Open on Benzinga Other news Barclays Downgrades Fresenius Medical Care to Underweight Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ImmunityBio And Rafa Laboratories Say Israeli MoH Grants Approval For ANKTIVA, Indicated In Combination With BCG For Treatment Of Adult Patients With BCG-Unresponsive NMIBC With CIS With Or Without Papillary Tumors Monte Rosa Therapeutics Presents Preclinical Data Of MRT-8102 At ACR Convergence 2026 B of A Securities Initiates Coverage On Supernus with Buy Rating, Announces Price Target of $47 Freedom Broker Upgrades Dnow to Buy, Maintains Price Target to $18
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
ImmunityBio And Rafa Laboratories Say Israeli MoH Grants Approval For ANKTIVA, Indicated In Combination With BCG For Treatment Of Adult Patients With BCG-Unresponsive NMIBC With CIS With Or Without Papillary Tumors
